Hepatitis C Outcomes Research
The ICORN registry assesses and records treatment outcomes from emerging HCV therapeutics using data from real-life clinical practice. In January 2012, the protease inhibitors boceprevir and telaprevir were found to be cost-effective in the Irish setting. This is a multi-centred, observational, cohort research study. The aim of the registry is to prospectively collect national clinical (effectiveness, safety and tolerability) and economic outcomes data from all HCV-infected patients (all genotypes) treated for hepatitis C, to populate a database, to analyse the results and produce reports and research papers.
The objectives of the research are:
a) To compare clinical trial outcome data with real world data
b) To assess the total costs associated with treating patients with triple therapy
c) To determine the safety and tolerability of triple therapy in the real world setting
This is the first prospective clinical and economic outcomes registry to be developed with multidisciplinary involvement from clinicians and healthcare providers in Ireland.